A Phase 3 interventional study of Vortioxetine and Placebo in Major Depressive Disorder, sponsored by Takeda. Completed at 32 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-11-11.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 29th largest by enrollment, is one of 5 that started in 2011, is one of 31 in phase 3, and was the 18th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 366 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
26 studies in Depressive Disorder, Major by Takeda: 1 open now, 1 under way, 1 of them phase 3. Of 25 finished, 24 (96%) have results posted.
Among the 26 studies in Depressive Disorder, Major by Takeda, this one is the 18th largest by enrollment of the 24 interventional ones that give a count, is one of 6 that started in 2011, is one of 16 in phase 3, and was the 12th registered.
Takeda’s Depressive Disorder, Major studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy, safety and tolerability of 8-week treatment with Vortioxetine (Lu AA21004), once daily (QD), in Japanese participants with major depressive disorder.
The purpose of this study is to assess the efficacy, safety and tolerability of 8-week treatment with Lu AA21004, once daily (QD), in Japanese participants with major depressive disorder.
Lu AA21004 was discovered by H. Lundbeck A/S, and is under co-development by H. Lundbeck A/S and Takeda for the treatment of major depressive disorder and general anxiety disorder. Major depressive disorder (MDD) is a chronic, recurring disease with considerable morbidity in the general population. The estimated lifetime prevalence of major depression in the adult population is 5 to 25%, with approximately 2-fold higher prevalence in women than in men. The hallmark of the disease is a depressed mood, with additional symptoms including sleep disturbances, psychomotor agitation or retardation, sexual dysfunction, weight loss, concentration difficulties and delusional ideas. In addition to direct ill effects, MDD causes suicide or job loss and exerts indirect influence on social economy. This study will assess the efficacy and the safety of Lu AA21004. This study consists of a 1-week screening period, an 8-week double-blind treatment period, 4-week safety follow-up.The duration of the study is 13 weeks in total. Blood samples will be collected from participants, and a safety follow-up contact (visit or phone call) will be made 4 weeks after completion of the 8-week double-blind treatment period. Subjects who complete the 8-week double-blind treatment period can successively enter a long-term extension study (Lu AA21004/OCT-001; NCT01395147; hereinafter, OCT-001), if they meet all inclusion criteria and none of exclusion criteria of the OCT-001 study and are willing to participate in the OCT-001 study. Subjects who will enter the OCT-001 will not be requested to safety follow-up after completion of the 8-week double-blind treatment period.
Lu AA21004 was discovered by H. Lundbeck A/S, and is under co-development by H. Lundbeck A/S and Takeda for the treatment of major depressive disorder and general anxiety disorder.
Major depressive disorder (MDD) is a chronic, recurring disease with considerable morbidity in the general population. The estimated lifetime prevalence of major depression in the adult population is 5 to 25%, with approximately 2-fold higher prevalence in women than in men. The hallmark of the disease is a depressed mood, with additional symptoms including sleep disturbances, psychomotor agitation or retardation, sexual dysfunction, weight loss, concentration difficulties and delusional ideas. In addition to direct ill effects, MDD causes suicide or job loss and exerts indirect influence on social economy.
This study will assess the efficacy and the safety of Lu AA21004. This study consists of a 1-week screening period, an 8-week double-blind treatment period, 4-week s safety follow-up.The duration of the study is 13 weeks in total. Blood samples will be collected from participants, and a safety follow-up contact (visit or phone call) will be made 4 weeks after completion of the 8-week double-blind treatment period.
Subjects who complete the 8-week double-blind treatment period can successively enter a long-term extension study (Lu AA21004/OCT-001; NCT01395147; hereinafter, OCT-001), if they meet all inclusion criteria and none of exclusion criteria of the OCT-001 study and are willing to participate in the OCT-001 study.
Subjects who will enter the OCT-001 will not be requested to safety follow-up after completion of the 8-week double-blind treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The subject has one or more of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vortioxetine 5 mg, tablets, orally, once daily for up to 8 weeks.
Drug: Vortioxetine
Vortioxetine 10 mg, tablets, orally, once daily for up to 8 weeks.
Drug: Vortioxetine
Vortioxetine placebo-matching tablets, orally, once daily for up to 8 weeks.
Drug: Placebo
Vortioxetine tablets
Also known as: Lu AA21004, BRINTELLIX
Vortioxetine placebo
Also known as: Vortioxetine placebo-matching tablets
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score After 8 Weeks of Treatment
MADRS is a 10-item clinician rated scale that measures overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates that symptoms have improved. An analysis of covariance (ANCOVA) model was used with change in MADRS total score as a dependent variable, treatment as a fixed effect and the baseline MADRS total score as a covariate.
Time frame: Baseline, Week 8
Percentage of Patients With MADRS Response After 8 Weeks of Treatment
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. Response is defined as a ≥50% decrease in the MADRS Total Score from Baseline.
Time frame: Baseline, Week 8
Percentage of Patients With MADRS Remission After 8 Weeks of Treatment
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. Remission is defined as a MADRS Total Score ≤10.
Time frame: Week 8
Change From Baseline in the Hamilton Depression Scale (HAM-D17) Total Score After 8 Weeks of Treatment
The HAM-D17 is a 17-item rating scale that assesses depressed mood, agitation and somatic symptoms of depression, rated on a 5-point scale from 0 (absent) to 4 (very severe) with a total score range from 0 to 52. Higher scores indicate greater severity of depression symptoms. A negative change from Baseline indicates that symptoms have improved. ANCOVA model was used with treatment as a fixed effect and the baseline HAM-D17 score as a covariate.
Time frame: Baseline, Week 8
Clinical Global Impression Scale-Improvement (CGI-I) Score After 8 Weeks of Treatment
The CGI-I assesses the clinician's impression of the participant's state of mental illness improvement and consists of one question for the investigator: "Compared to his condition at the start of the study, how much has this patient changed?" which is rated on a seven-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse). Higher scores indicate greater severity of illness. Values closest to 1 for this outcome measure indicate the greatest improvement of symptoms. ANCOVA model was used with treatment as a fixed effect and the baseline CGI-Severity (CGI-S) score as a covariate.
Time frame: Baseline, Week 8
Change From Baseline in Sheehan Disability Scale (SDS) Total Score After 8 Weeks of Treatment
The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely) with a total score range from 0 to 30. Higher scores indicate greater severity of impairment. A negative change from Baseline indicates that symptoms have improved. ANCOVA model was used with treatment as a fixed effect and the Baseline SDS total score as a covariate.
Time frame: Baseline, Week 8
Participants took part in the study at 32 investigative sites throughout Japan from 13 May 2011 to 21 December 2012.
| Milestone | Vortioxetine 5 mg | Vortioxetine 10 mg | Placebo |
|---|---|---|---|
| Started | 119 | 123 | 124 |
| Completed | 112 | 113 | 113 |
| Not completed | 7 | 10 | 11 |
| Withdrew: Pretreatment event or adverse event | 3 | 4 | 6 |
| Withdrew: Major protocol deviation | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Withdrawal of consent | 2 | 3 | 3 |
| Withdrew: Lack of efficacy | 2 | 1 | 1 |
| Withdrew: Non compliance with study medication | 0 | 1 | 0 |
MADRS is a 10-item clinician rated scale that measures overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates that symptoms have improved. An analysis of covariance (ANCOVA) model was used with change in MADRS total score as a dependent variable, treatment as a fixed effect and the baseline MADRS total score as a covariate.
| scores on a scale | Vortioxetine 5 mg | Vortioxetine 10 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score After 8 Weeks of Treatment | -15.84 ± 0.885 | -14.85 ± 0.874 | -13.81 ± 0.870 |
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. Response is defined as a ≥50% decrease in the MADRS Total Score from Baseline.
| percentage of participants | Vortioxetine 5 mg | Vortioxetine 10 mg | Placebo |
|---|---|---|---|
| Percentage of Patients With MADRS Response After 8 Weeks of Treatment | 51.3 | 45.9 | 39.8 |
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. Remission is defined as a MADRS Total Score ≤10.
| percentage of participants | Vortioxetine 5 mg | Vortioxetine 10 mg | Placebo |
|---|---|---|---|
| Percentage of Patients With MADRS Remission After 8 Weeks of Treatment | 29.4 | 28.7 | 22.0 |
The HAM-D17 is a 17-item rating scale that assesses depressed mood, agitation and somatic symptoms of depression, rated on a 5-point scale from 0 (absent) to 4 (very severe) with a total score range from 0 to 52. Higher scores indicate greater severity of depression symptoms. A negative change from Baseline indicates that symptoms have improved. ANCOVA model was used with treatment as a fixed effect and the baseline HAM-D17 score as a covariate.
| scores on a scale | Vortioxetine 5 mg | Vortioxetine 10 mg | Placebo |
|---|---|---|---|
| Change From Baseline in the Hamilton Depression Scale (HAM-D17) Total Score After 8 Weeks of Treatment | -9.56 ± 0.586 | -8.54 ± 0.580 | -8.40 ± 0.578 |
The CGI-I assesses the clinician's impression of the participant's state of mental illness improvement and consists of one question for the investigator: "Compared to his condition at the start of the study, how much has this patient changed?" which is rated on a seven-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse). Higher scores indicate greater severity of illness. Values closest to 1 for this outcome measure indicate the greatest improvement of symptoms. ANCOVA model was used with treatment as a fixed effect and the baseline CGI-Severity (CGI-S) score as a covariate.
| scores on a scale | Vortioxetine 5 mg | Vortioxetine 10 mg | Placebo |
|---|---|---|---|
| Clinical Global Impression Scale-Improvement (CGI-I) Score After 8 Weeks of Treatment | 2.44 ± 0.100 | 2.57 ± 0.099 | 2.66 ± 0.099 |
The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely) with a total score range from 0 to 30. Higher scores indicate greater severity of impairment. A negative change from Baseline indicates that symptoms have improved. ANCOVA model was used with treatment as a fixed effect and the Baseline SDS total score as a covariate.
| scores on a scale | Vortioxetine 5 mg | Vortioxetine 10 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Sheehan Disability Scale (SDS) Total Score After 8 Weeks of Treatment | -5.01 ± 0.510 | -4.02 ± 0.506 | -2.91 ± 0.504 |
Collected over 8-week double blind treatment period and 4-week follow-up safety period, or up to 4 weeks after withdrawal visit, excluding those who enrolled in the long-term extension study (Up to 12 Weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vortioxetine 5 mg | — | 1/119 (0.8%) | 80/119 (67.2%) |
| Vortioxetine 10 mg | — | 1/122 (0.8%) | 93/122 (76.2%) |
| Placebo | — | 1/124 (0.8%) | 78/124 (62.9%) |
| Event | Vortioxetine 5 mg | Vortioxetine 10 mg | Placebo |
|---|---|---|---|
| Brain contusionInjury, poisoning and procedural complications | 1/119 | 0/122 | 0/124 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/119 | 0/122 | 0/124 |
| Cerebral haematomaNervous system disorders | 1/119 | 0/122 | 0/124 |
| Subarachnoid haemorrhageNervous system disorders | 1/119 | 0/122 | 0/124 |
| Suicidal behaviourPsychiatric disorders | 0/119 | 1/122 | 0/124 |
| Breast cancer recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/119 | 0/122 | 1/124 |
| Event | Vortioxetine 5 mg | Vortioxetine 10 mg | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 20/119 | 35/122 | 9/124 |
| NasopharyngitisInfections and infestations | 24/119 | 17/122 | 21/124 |
| DiarrhoeaGastrointestinal disorders | 10/119 | 13/122 | 10/124 |
| SomnolenceNervous system disorders | 7/119 | 12/122 | 9/124 |
| HeadacheNervous system disorders | 10/119 | 6/122 | 8/124 |
| Suicidal ideationPsychiatric disorders | 1/119 | 8/122 | 2/124 |
| Blood creatine phosphokinase increasedInvestigations | 5/119 | 1/122 | 5/124 |
| ConstipationGastrointestinal disorders | 2/119 | 5/122 | 4/124 |
| ThirstGeneral disorders | 3/119 | 5/122 | 3/124 |
| DizzinessNervous system disorders | 2/119 | 5/122 | 2/124 |
| Age, Continuous(years) | Vortioxetine 5 mg | Vortioxetine 10 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 38.8 ± 10.85 | 38.8 ± 10.99 | 37.6 ± 10.67 | 38.4 ± 10.83 |
| Sex: Female, Male(Participants) | Vortioxetine 5 mg | Vortioxetine 10 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 50 | 54 | 67 | 171 |
| Male | 69 | 69 | 57 | 195 |
| Region of Enrollment(participants) | Vortioxetine 5 mg | Vortioxetine 10 mg | Placebo | Total |
|---|---|---|---|---|
| Japan | 119 | 123 | 124 | 366 |
| Height(cm) | Vortioxetine 5 mg | Vortioxetine 10 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 165.7 ± 8.45 | 165.6 ± 8.51 | 163.9 ± 8.46 | 165.1 ± 8.49 |
| Weight(kg) | Vortioxetine 5 mg | Vortioxetine 10 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 62.18 ± 11.357 | 62.11 ± 15.883 | 60.86 ± 12.690 | 61.71 ± 13.441 |
| Body Mass Index (BMI)(kg/m^2) | Vortioxetine 5 mg | Vortioxetine 10 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 22.59 ± 3.366 | 22.42 ± 4.306 | 22.57 ± 4.016 | 22.53 ± 3.911 |
| Cytochrome p450 (CYP)2D6 Phenotype(participants) | Vortioxetine 5 mg | Vortioxetine 10 mg | Placebo | Total |
|---|---|---|---|---|
| Ultra-rapid Metabolizer (UM) | 1 | 1 | 2 | 4 |
| Extensive Metabolizer (EM) | 91 | 97 | 96 | 284 |
| Intermediate Metabolizer (IM) | 25 | 20 | 21 | 66 |
| Poor Metabolizer (PM) | 0 | 1 | 0 | 1 |
| Unknown | 2 | 4 | 5 | 11 |
| Smoking Classification(participants) | Vortioxetine 5 mg | Vortioxetine 10 mg | Placebo | Total |
|---|---|---|---|---|
| Current smoker | 39 | 41 | 40 | 120 |
| Ex-smoker | 26 | 24 | 24 | 74 |
| Never Smoked | 54 | 58 | 60 | 172 |
7 further baseline measures are reported on the registry.
The record gives a start of May 2011, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine